Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

CD133+ cancer stem cells in lung cancer.

Wang S, Xu ZY, Wang LF, Su W.

Front Biosci (Landmark Ed). 2013 Jan 1;18:447-53.

PMID:
23276935
2.

CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer.

Cui F, Wang J, Chen D, Chen YJ.

Oncol Rep. 2011 Mar;25(3):701-8. doi: 10.3892/or.2010.1115. Epub 2010 Dec 20.

PMID:
21174061
3.

Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells.

Hsu HS, Huang PI, Chang YL, Tzao C, Chen YW, Shih HC, Hung SC, Chen YC, Tseng LM, Chiou SH.

Cancer. 2011 Jul 1;117(13):2970-85. doi: 10.1002/cncr.25869. Epub 2011 Jan 10.

4.

High expression of octamer-binding transcription factor 4A, prominin-1 and aldehyde dehydrogenase strongly indicates involvement in the initiation of lung adenocarcinoma resulting in shorter disease-free intervals.

Cortes-Dericks L, Galetta D, Spaggiari L, Schmid RA, Karoubi G.

Eur J Cardiothorac Surg. 2012 Jun;41(6):e173-81. doi: 10.1093/ejcts/ezs170. Epub 2012 Apr 23.

PMID:
22529186
5.

The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.

Le H, Zeng F, Xu L, Liu X, Huang Y.

Mol Med Rep. 2013 Nov;8(5):1511-8. doi: 10.3892/mmr.2013.1667. Epub 2013 Sep 4.

PMID:
24008862
6.

TGF-β1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction.

Tirino V, Camerlingo R, Bifulco K, Irollo E, Montella R, Paino F, Sessa G, Carriero MV, Normanno N, Rocco G, Pirozzi G.

Cell Death Dis. 2013 May 2;4:e620. doi: 10.1038/cddis.2013.144.

7.

Differential Expression of Cancer Stem Cell Markers ALDH1 and CD133 in Various Lung Cancer Subtypes.

Roudi R, Korourian A, Shariftabrizi A, Madjd Z.

Cancer Invest. 2015;33(7):294-302. doi: 10.3109/07357907.2015.1034869. Epub 2015 Jun 5.

PMID:
26046383
8.

The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer.

Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, Viglietto G, Rocco G, Pirozzi G.

Eur J Cardiothorac Surg. 2009 Sep;36(3):446-53. doi: 10.1016/j.ejcts.2009.03.063. Epub 2009 May 22.

PMID:
19464919
9.

CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.

Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J, Herr I.

Int J Cancer. 2010 Feb 15;126(4):950-8. doi: 10.1002/ijc.24822.

10.

CD133+ subpopulation of the HT1080 human fibrosarcoma cell line exhibits cancer stem-like characteristics.

Feng BH, Liu AG, Gu WG, Deng L, Cheng XG, Tong TJ, Zhang HZ.

Oncol Rep. 2013 Aug;30(2):815-23. doi: 10.3892/or.2013.2486. Epub 2013 May 23.

PMID:
23708735
11.

Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.

Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, Caserini R, Lo Vullo S, Camerini T, Mariani L, Delia D, Calabrò E, Pastorino U, Sozzi G.

Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16281-6. doi: 10.1073/pnas.0905653106. Epub 2009 Sep 10.

12.

CD133 and non-small-cell lung cancer.

Wiwanitkit V.

Eur J Cardiothorac Surg. 2010 Apr;37(4):988; author reply 988-9. doi: 10.1016/j.ejcts.2009.10.027. Epub 2009 Nov 28. No abstract available.

PMID:
19945887
13.

Biologic characteristics of the side population of human small cell lung cancer cell line H446.

Wang B, Yang H, Huang YZ, Yan RH, Liu FJ, Zhang JN.

Chin J Cancer. 2010 Mar;29(3):254-60.

14.

CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).

Choijamts B, Jimi S, Kondo T, Naganuma Y, Matsumoto T, Kuroki M, Iwasaki H, Emoto M.

Stem Cells. 2011 Oct;29(10):1485-95. doi: 10.1002/stem.711.

15.

Galectin-1 is overexpressed in CD133+ human lung adenocarcinoma cells and promotes their growth and invasiveness.

Zhou X, Li D, Wang X, Zhang B, Zhu H, Zhao J.

Oncotarget. 2015 Feb 20;6(5):3111-22.

16.

Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells.

Tseng LM, Huang PI, Chen YR, Chen YC, Chou YC, Chen YW, Chang YL, Hsu HS, Lan YT, Chen KH, Chi CW, Chiou SH, Yang DM, Lee CH.

J Pharmacol Exp Ther. 2012 May;341(2):410-23. doi: 10.1124/jpet.111.188730. Epub 2012 Feb 10.

17.

Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties.

Leung EL, Fiscus RR, Tung JW, Tin VP, Cheng LC, Sihoe AD, Fink LM, Ma Y, Wong MP.

PLoS One. 2010 Nov 19;5(11):e14062. doi: 10.1371/journal.pone.0014062.

18.

Both CD133+ and CD133- subpopulations of A549 and H446 cells contain cancer-initiating cells.

Meng X, Li M, Wang X, Wang Y, Ma D.

Cancer Sci. 2009 Jun;100(6):1040-6. doi: 10.1111/j.1349-7006.2009.01144.x. Epub 2009 Feb 20.

19.

Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review.

Qu H, Li R, Liu Z, Zhang J, Luo R.

Int J Clin Exp Pathol. 2013 Oct 15;6(11):2644-50. eCollection 2013. Review.

20.

Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells.

Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, Ku HH, Chiou SH.

PLoS One. 2008 Jul 9;3(7):e2637. doi: 10.1371/journal.pone.0002637.

Supplemental Content

Support Center